Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Cue Biopharma, Inc.

NASDAQ: CUE · Life Sciences · 5 alerts · CIK 1645460

Share price
$14.10Close, Nov 16
Market cap
$102M
Shares outstanding
7.26MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Cue Biopharma, Inc. filings on SEC EDGAR ↗

6:34 PM ET 8-K
Financial Results

Cue Biopharma Financial Results

Cue Biopharma reported third quarter 2026 financial results and highlighted the initiation of first-in-human dosing for CUE-401, its first autoimmune therapeutic candidate. The company also shared positive Phase 2 findings for CUE-221 in chronic spontaneous urticaria (CSU), demonstrating statistically significant hives resolution and potential differentiation from existing therapies like Xolair.

Term
Q3 2026

“We are seeing exciting momentum across our portfolio. We believe CUE-221 has the potential to redefine treatment of IgE-mediated diseases by delivering deeper, more durable disease control and expanding the population of patients who can benefit from anti-IgE therapy.”

Pasha Sarraf, M.D., Ph.D., chairman of the board of Cue Biopharma

“Our goal is to move beyond partial protection toward more complete, sustained protection for patients, including those with high baseline IgE who remain underserved by current therapies. In parallel, we are advancing half-life extension efforts for CUE-221, aimed at further enhancing patient convenience.”

Shao-Lee Lin, M.D., Ph.D., president and chief executive officer of Cue Biopharma

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.